Homologous Recombination Deficiency clinical trials at UCSF

1 research study open to eligible people

Homologous recombination deficiency is when cells cannot fix certain DNA breaks properly. UCSF is testing new medicines that target tumors with this defect. Some studies check safety and dose in people with advanced solid tumors.

Showing trials for

  • Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    open to eligible people ages 18 years and up

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

    San Francisco, California and other locations

Our lead scientists for Homologous Recombination Deficiency research studies include .

Last updated: